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Epicatechin gallate (ECg) sensitizes methicillin-resistant
Staphylococcus aureus (MRSA) to oxacillin and other -lactam
agents; it also reduces the secretion of virulence-associated pro-
teins, prevents biofilm formation, and induces gross morpho-
logical changes in MRSA cells without compromising the
growth rate. MRSA is resistant to oxacillin because of the pres-
enceof penicillin-bindingprotein 2a (PBP2a),which allowspep-
tidoglycan synthesis to continue after oxacillin-mediated acyla-
tion of native PBPs. We show that ECg binds predominantly to
the cytoplasmic membrane (CM), initially decreasing the fluid-
ity of the bilayer, and induces changes in gene expression indic-
ative of an attempt to preserve and repair a compromised cell
wall. On further incubation, the CM is reorganized; the amount
of lysylphosphatidylglycerol is markedly reduced, with a con-
comitant increase in phosphatidylglycerol, and the proportion
of branched chain fatty acids increases, resulting in amore fluid
structure. We found no evidence that ECg modulates the enzy-
matic activity of PBP2a through direct binding to the protein
but determined that PBP2 is delocalized from the FtsZ-an-
chored cell wall biosynthetic machinery at the septal division
site following intercalation into the CM. We argue that many
features of the ECg-induced phenotype can be explained by
changes in the fluid dynamics of the CM.
Staphylococcus aureus is an opportunistic pathogen respon-
sible for hospital- and community-acquired infections that
extend from localized cutaneous lesions to life-threatening
conditions such as sepsis and infective endocarditis (1, 2).
Staphylococcal infections are becoming increasingly difficult to
treat because of the rapid emergence ofmultidrug resistance. In
particular, the acquisition, evolution, and horizontal dissemi-
nation of genes conferring resistance to -lactam antibiotics
have eroded the capacity to employ these agents for effective
chemotherapy (3, 4). Although new agents such as linezolid,
daptomycin, and tigecycline have been developed in response
to evolving resistance in Gram-positive pathogens and are
proving highly effective (5), resistance to these drugs is emerg-
ing (6, 7) and is likely to increase as their clinical use increases.
There is a continuing need for new treatments for these infec-
tions, in particular those employing agents that suppress or
abrogate the emergence of resistance (8). The utility of antibi-
otics made less potent by the evolution of resistance could be
restored by compounds with the capacity to reverse antibiotic
resistance during the course of infection; such modifying
agents, that generate new phenotypes rather than kill the target
bacteria, may have the potential to reduce the emergence of
resistance to drug-modifier combinations (9).
In this context, we are examining the therapeutic anti-staph-
ylococcal potential of ()-epicatechin gallate (ECg),4 a poly-
phenol found in abundance in green tea (10). Galloyl catechins
have negligible intrinsic antibacterial activity but reduce peni-
cillin-binding protein 2a (PBP2a)-mediated -lactam resis-
tance (11); they also disrupt the secretion of virulence-related
proteins (9) and prevent the formation of biofilms (12, 13). In
addition, they promote cell wall thickening and cell aggregation
without affecting the rate or extent of growth in culture (12, 14).
ECg, the most potent galloyl catechin (10, 11), does not sup-
press the transcription ofmecA or the production of its product
PBP2a (12), and it is clear that restoration of susceptibility of
methicillin-resistant S. aureus (MRSA) to -lactam antibiotics
is due to amore complex and as yet incompletely definedmech-
anism.There is some evidence that ECg-mediatedmodification
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of staphylococci is related to the capacity of galloyl catechins to
partition into the cytoplasmicmembrane (CM). ECgpenetrates
the lipid palisade of unilamellar vesicles of phosphatidylcholine
or phosphatidylethanolamine, increasing the lipid order of the
fluid bilayers (15–18). ECg and other catechins bind to MRSA
during the mid-logarithmic phase of growth to a degree that
reflects their capacity to intercalate into phosphatidylcholine
and phosphatidylethanolamine bilayers (19). However, S.
aureus elaborates an unusual CM comprising three major
phospholipids (20–22): negatively charged phosphatidylglyc-
erol (PG) and cardiolipin in addition to positively charged
lysyl-PG (LPG), with evidence for asymmetric distribution
across the outer and inner CM leaflets (21). The intercalation of
catechins into the CM of viable staphylococci has yet to be
demonstrated.
ECg-mediated perturbation of orderly cell division, cell wall
turnover, and cell separation may be related to changes in the
secretion of autolysins from the staphylococcal cell; ECg-grown
cells retained autolysinswithin the thickened cell wall, probably
in a predominantly inactive form, with greatly reduced
amounts released into the growth medium (12). Activity and
retention of these enzymes, key players in cell separation and
peptidoglycan turnover, are strongly influenced by the charge
characteristics of the cell wall; growth in the presence of ECg
decreases the net positive charge of the cell surface (9, 23), in
part by reducing the degree of D-alanylation of wall teichoic
acids associatedwith peptidoglycan (23). An increased negative
surface charge leads to electrostatic repulsion from negatively
charged surfaces and in all likelihood accounts for the biofilm
inhibiting properties of ECg (24). Further, ECg modulates the
levels of PBPs 1 and 3 in the staphylococcal CM, resulting in a
5–10% reduction in peptidoglycan cross-linking without com-
promising cell integrity (12) and is responsible for the less dense
appearance of the wall and the greater packed cell volume of
ECg-treated bacteria (23).
Although these changes explain some aspects of the complex
ECg-induced MRSA phenotype, they are unlikely to account
for the profound changes in-lactam susceptibility engendered
by ECg; moderate concentrations elicit complete restoration of
oxacillin sensitivity (11, 19), and we contend that such a large
consequence can only be achieved by direct interference with
the underlying antibiotic resistance machinery of the cell. In
dividing cells, PBP2-mediated transglycosylation and transpep-
tidation reactions occur predominantly at the division septum
(25). The PBP2 substrate within extending peptidoglycan
chains is restricted to the septum; PBP2molecules are recruited
to this site by a process requiring the presence of FtsZ, a protein
that directly or indirectly anchors the cell wall synthetic
machinery to the site of cell division (26). -Lactam antibiotics
bind covalently to the transpeptidase active site of PBP2 and
abrogate catalytic activity, preventing formation of pentagly-
cine cross-bridges and, in -lactam-susceptible strains, delo-
calizing PBP2 from the septum (26). The acquisition of PBP2a
allows transpeptidation to occur in the presence of -lactam
agents (27); in its native conformation, PBP2a has a very low
affinity for -lactams because of the closed conformation of
its active site (28). PBP2 and PBP2a function cooperatively in
the presence of oxacillin, possibly as amultienzyme complex, to
ensure orderly peptidoglycan synthesis at the septum with no
delocalization of PBP2 (26). Intercalation of ECg into theCMof
dividing MRSA may interfere with the traffic of membrane-
anchored PBPs; in addition, exposure of PBP2a to ECg may
result in a conformational change leading to the opening of the
active site from the closed conformation and the concomitant
loss of resistance. In this study, we investigated binding of ECg
to theCM, the effect of ECg on PBP2 localization, and its capac-
ity to alter the conformation of PBP2a. Our data show that ECg
penetrates the staphylococcal CM, initially decreasing mem-
brane fluidity; the targeted bacteria respond by elaborating a
moremobile andmore negatively charged bilayer. ECg does not
appear to interact with PBP2a or alter its interactions with
-lactams but delocalizes PBP2 from the septum; we suggest
that delocalization of PBP2 from the site of cell division is pri-
marily responsible for galloyl catechin-mediated sensitization
of MRSA strains to -lactam antibiotics.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Reagents—Epidemic MRSA isolate
EMRSA-16 was from a clinical sample obtained at the Royal
Free Hospital (London, UK). Methicillin-susceptible S. aureus
strain ATCC29213 was obtained from the American Type Cul-
ture Collection; vancomycin-intermediate-resistant S. aureus
(VISA) Mu50 was isolated from a Japanese patient in 1997.
Methicillin-susceptible S. aureus strain LH607 is a protein
A-deficientmutant constructed in the background of 8325-4 by
inactivation of the spa gene using a tetracycline cassette. COL
spa was obtained by transduction of the inactivated spa
gene from LH607 into COL. The homogeneous MRSA strain
COLpPBP2-31, derived from COL, carries a gfp-pbp2 fusion
(26). RUSA130 (29) is a COL mutant in which PBP2 has been
inactivated by insertion of Tn551 (EryR) into the transpepti-
dase-encoding region of pbp2; this strain was the gift of A.
Tomasz (Rockefeller University, New York, NY). The mini-
mum inhibitory concentration (MIC) of S. aureus strains was
determined as described previously (11). ECg and ()-[4(n)-
3H] ECg were gifts from Mitsui Norin (Tokyo, Japan); the
radiolabeled compound (specific activity, 481 GBq/mmol;
radioactive concentration, 74.0 MBq/ml), was prepared from
sodium boro[3H]hydride by Amersham Biosciences using a
proprietary method developed by Amersham Biosciences. PG
and cardiolipin were obtained from Sigma-Aldrich; LPG was
produced by custom synthesis (Avanti Polar Lipids Inc., Delfzijl,
TheNetherlands). The bacteriawere grownwith aeration at 37 °C
in Mueller-Hinton (MH) broth (Oxoid Ltd., Basingstoke, UK).
Erythromycin (10g/ml) and tetracycline (5g/ml)wereaddedas
necessary. ECg was dissolved in 50% ethanol and added to MH
broth to give a final concentration of 12.5g/ml.
Microarray Analysis—The BG@S SAv1.1.0 microarray has
been described elsewhere (30) and contains PCR products rep-
resenting all predicted open reading frames from the initial
seven S. aureus genome sequencing projects. Total RNA
extractswere prepared as described previously (31). EMRSA-16
was grown in the presence of ECg until the A600 reached 0.7
(logarithmic phase) or 3.0 (stationary phase). Hybridizations
were performed as described (31).Hybridization datawere ana-
lyzed using an Affymetrix 428 scanner and then quantified
ECg-mediated Disruption of-Lactam Resistance
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usingBluefuse forMicroarrays 3.5 software (BlueGnome,Cam-
bridge,UK).Data analysiswas performed inGeneSpringGX7.3
(Agilent Technologies, Santa Clara, CA) usingmedian-normal-
ized Cy5/Cy3 ratio intensities for three biological replicates as
described previously (31). Fully annotatedmicroarray data have
been deposited in BG@Sbase (accession number BUGS-97)
and ArrayExpress (accession number E-BUGS-97). The modu-
lation of selected genes by ECg was confirmed using quantita-
tive reverse transcription-PCR as described previously (31).
Localization of [3H]ECg in S. aureus—EMRSA-16 was grown
in MH broth containing ECg and [3H]ECg (3.7 KBq/ml); the
cells were harvested by centrifugation once the A600 had
reached 0.6–0.8 and washed twice with cold Buffer A (0.05 M
Tris-HCl, pH 7.5, containing 100 mM NaCl and 20 mM
MgCl26H2O). Washed cells were suspended in Buffer A con-
taining 50% (w/v) sucrose and converted to protoplasts by incu-
bation with lysostaphin (200g/ml) for 2 h at 37 °C with gentle
swirling. Control cells were incubatedwithout lysostaphin. The
protoplasts were harvested by centrifugation (38,000  g, 1 h,
4 °C), and the supernatant was retained for determination of
radioactivity. The protoplasts were then lysed by dilution in
excess of 50 mM phosphate buffer, pH 6.6, containing 10 mM
MgCl26H2O, 5 g/ml DNase, and 5 g/ml RNase. The lysates
were incubated for 15 min at 37 °C with shaking (200 rpm).
EDTA was added to a final concentration of 10 mM, and the
lysates were incubated for a further 15 min; MgCl26H2O was
added to give a final concentration of 15mM, and residualwhole
cells and cell debris were removed by centrifugation (2,000 g,
4 °C, 30 min). The membrane fraction was harvested by centri-
fugation (130,000 g, 1 h, 4 °C), and radioactivity in the pellet
and supernatant was measured. The values obtained from par-
allel control experiments omitting the cell wall hydrolase lyso-
staphin were subtracted from values using lysostaphin-treated
cells to compensate for nonspecific [3H]ECg release.
Phospholipid Analysis—To determine the nature of the head
groups of CM phospholipids, 100-ml cultures of EMRSA-16
were grown inMHbroth containing [32P]orthophosphate (18.5
KBq/ml). Phospholipids were extracted during mid-logarith-
mic phase (A600  0.7) according to Bligh and Dyer (32) and
separated as described by Ames (33) with the exception that
high performance TLC glass plates were used (coated with Sil-
icaGel 60 F254, 100 100mm;Merck). The first dimensionwas
developed in chloroform,methanol, 7 N ammonia (60:35:5, v/v/
v), and the second was developed in chloroform,methanol, gla-
cial acetic acid (65:25:8, v/v/v). Radioactive spots were visual-
ized by autoradiography, identified by comparison with
commercial standards or by MS/MS, and quantified using a
Bio-Rad Molecular Imager FX. Fatty acid esters were hydro-
lyzed with MeOH, 20 M NaOH (19:1) for 30 min at 45 °C. Two
volumes ofCH2Cl2 and 1 volumeofwaterwere then added. The
samples were mixed and centrifuged, and the organic layer was
collected and evaporated. TMS derivatives were obtained using
50 l of acetonitrile and 50 l ofN,O-bis(trimethylsilyl)trifluo-
roacetamide (30 min, 80 °C). The derivatives were separated by
gas chromatography and identified by MS using combined gas
chromatography-MS comprising an Agilent HP HP6890 series
gas chromatography with HP7683 series injector interfaced
directly to an Agilent HP5973 mass selective detector (mass
range, 10–700 m/z; scan acquisition mode); a J &W DB-5ms
capillary column (40 m length, 250.0 m diameter, 0.25-m
film thickness) was installed, and an oven temperature gradient
of 80–280 °C was employed.
Cell Membrane Labeling and Fluorescence Anisotropy
Measurements—The membrane fluidity of mid-logarithmic
EMRSA-16 was determined by measuring the fluorescence
polarization of the probe 1,6-diphenyl-1,3,5-hexatriene (DPH)
inserted into theCMas previously described (34). Fluorescence
polarization was measured using a thermostat-controlled
PerkinElmer Life Sciences LS55 luminescence spectrometer.
The excitation and emission wavelengths for the DPH probe
were 358 and 428 nm, respectively. The data were analyzed
using FL WINLAB software program, version 4.00.02.
Epifluorescence Microscopy—The bacteria were grown in
MH broth to A600 of 0.3; ECg (12.5 g/ml), oxacillin (4 g/ml),
or ECg  oxacillin (12.5 and 4 g/ml) were added to aliquots
and incubated (37 °C; 1 h). For phase contrast and fluorescence
microscopy, live cells were examined using an Axi Observer.Z1
inverted microscope (Zeiss) on glass slides coated with 1% aga-
rose in PBS. Image acquisition was undertaken with a Cool-
SNAP HQ2 camera (Photometrics, Tucson, AZ) and Meta-
morph versus 7.5 software (Molecular Devices, Uckfield, UK).
ImmunofluorescenceMicroscopy—ECg-, oxacillin-, and ECg/
oxacillin-treated bacteria were fixed and examined by fluores-
cence microscopy as described (25). Lysostaphin-treated cells
were washed with PBS, air-dried, rehydrated with PBS, blocked
with 2% bovine serum albumin for 15 min and incubated over-
night at 4 °C with the primary antibody against Bacillus subtilis
FtsZ added in consecutive 2-fold dilutions over the range
1/800–1/6,400. The cells were washed with PBS and incubated
in the dark for 1 h with anti-rabbit IgG fluorescein isothiocya-
nate conjugate diluted 1/500 in 2% bovine serum albumin
before further washing. Vectashieldmountingmedium (Vector
Laboratories, Peterborough, UK) containing 1 g/ml 4,6-dia-
midino-2-phenylindole was added before visualization by fluo-
rescence microscopy.
PBP Extraction and Profiling—CMswere prepared from log-
arithmic phase cultures, and PBPs were released from mem-
brane vesicles with 2% (v/v) Triton X-100 as described previ-
ously (12). Following exposure of PBP preparations (10 g of
protein) to ECg for 15 min at 37 °C, PBPs were selectively
labeled by preincubation with 25 M Bocillin FL (Invitrogen)
for 10 min at 37 °C. The proteins were then separated by 10%
SDS-PAGE, and PBPs were detected by fluorography using the
Bio-Rad FX imager.
Interactions with PBP2a—The capacity of ECg to bind
PBP2a was determined. Recombinant PBP2a was expressed
and purified as described earlier (35, 36). We ascertained that
the protein was soluble during all conditions of assay. Binding
studies were conducted with -lactams (Bocillin FL or
benzyl[14C]penicillin; specific activity of 59 mCi/mmol; Amer-
sham Biosciences) as acylating agents or [3H]ECg. The aliquots
were collected at different time intervals, proteins were sep-
arated by 10% SDS-PAGE, and the acyl-enzyme complex was
detected by fluorimetry (Gel Doc 2000; Bio-Rad) or scintil-
lation counting of gel slices. The kinetic parameters for
interactions of nitrocefin with PBP2a (acylation and deacy-
ECg-mediated Disruption of-Lactam Resistance
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lation studies) were measured as previously described (35).
Intrinsic tryptophan fluorescence of PBP2a was assayed
using an excitation wavelength of 295 nm (PerkinElmer Life
Sciences LS55 spectrofluorimeter).
RESULTS
Effect of ECg on Antibiotic Resistance—Incorporation of 12.5
g/ml ECg into the assay reduced theMIC of EMRSA-16 from
512 to 1 g/ml and Mu50 from 256 to 0.5 g/ml (n  3). The
compound had no effect on the vancomycin MIC of vancomy-
cin-susceptible EMRSA-16 (0.5 g/ml; n  6) or VISA isolate
Mu50 (2 g/ml; n 6).
ECg-induced Changes in Gene Expression—Transcriptional
profiling usingDNAmicroarrays can shed light onmechanisms
of drug action by providing a genome-wide view of the cellular
response to bioactive agents. Because gene expression in S.
aureus is markedly influenced by population density and envi-
ronmental cues (37), we determined transcriptional profiles of
mid-logarithmic and stationary phase ECg-containing cultures.
Statistically significant 2-fold or greater changes were found for
103 up-regulated and 166 down-regulated genes following
growth of EMRSA-16 in mid-logarithmic culture in compari-
son with bacteria cultured in ECg-free medium. After growth
with ECg to stationary phase, 102 genes were up-regulated and
102were down-regulated comparedwith culture in the absence
of the galloyl catechin.
Genes up-regulated by growth to mid-logarithmic phase in
ECg were involved in cation transport and binding (fhuABD
and sstABCD), transport and metabolism of amino acids (e.g.
MRSA252 ORFs SAR0119–0127) and riboflavin (ribADEH),
electron transport (cydAB), -lactamase expression (blaIR1Z),
shape determination (e.g. mreC), and pathogenesis (e.g. fnbA
and isaA). Most prominent was the induction of genes belong-
ing to the general cell wall stress stimulon (Table 1), a group of
genes that are induced following treatment with cell wall active
antibiotics such as vancomycin, oxacillin, D-cycloserine, and
Bacitracin (38–40) and with CM depolarizing agents such as
daptomycin (41) and cationic defense peptides (42). Many
genes of the stimulon are under the control of the two compo-
nent signal transduction system vraRS, a positive regulator of
peptidoglycan synthesis (39), initially shown to be up-regulated
by exposure to vancomycin (39) and overexpressed in VISA
clinical isolates in comparison with the isogenic vancomycin-
susceptible parent (40). ECg increased transcription of the
response regulator vraR and the sensor histidine kinase vraS
(Table 1) and some, but not all, genes in the regulon controlled
by vraRS (39); thus, sgtB and fmt, involved in cell envelope bio-
genesis, pbpB (encoding PBP2), yvqF, tcaA (implicated in teico-
plainin resistance), prsA (protease maturation), and N315
ORFs SA2220, SA1703, SA1712, SA2103, SA2221, and SA2343
were up-regulated following exposure to ECg (Table 1). These
genes belong to the “core” cell wall stress stimulon, defined as
genes common to the four initial studies defining the stimulon
(40); genes from this core group that were not up-regulated by
ECg included murZ, involved in cell wall and membrane bio-
genesis, the serine protease encoding htrA, and SA2297. Some
stimulon-related genes of unknown function were highly up-
regulated by ECg, in particular vraX, annotated on the basis of
its up-regulation by imipenem, and SA1477 (24.4- and 11.9-fold
respectively; Table 1). The profile presented in Table 1 provides
strong evidence that EMRSA-16 responds to ECg by taking
steps to preserve and/or repair the cell wall and CM compro-
mised by exposure to this agent (43).
EMRSA-16 genes down-regulated by ECg in mid-logarith-
mic cultures fell into a number of functional categories, includ-
ing genes encoding osmotic shock proteins, membrane and
exported proteins and lipoproteins, genes involved in nitrate/ni-
trite, amino acid and carbohydrate metabolism, and protein and
ion transport. In addition, genesof theagr regulon (agrABCDI and
agrIII), controlling the expression of proteins involved in patho-
genesis, were strongly down-regulated. Gene transcriptional anal-
ysis following growth in the presence of ECg to stationary phase
gave no evidence that the cell wall stress stimulonwasmaintained
into this phase of the growth cycle.
Microarrays were validated using quantitative reverse tran-
scription-PCR on selected genes. There was excellent correla-
tion between quantitative reverse transcription-PCR and
microarray data for the 11 genes described in supple-
mental Fig. S1 (R2 0.9448; p 0.0000121).
Subcellular Localization of ECg—Prior to production of pro-
toplasts, the cells grown in the presence of [3H]ECg were
washed in buffer; in a typical experiment, 2–4% of total radio-
activity was recovered in the wash fraction. Nonspecific release
of radioactivity was determined by processing ECg-grown bac-
teria as described under “Experimental Procedures” with the
exception that lysostaphin was omitted from the first incuba-
tion step and the values obtained were subtracted from the
values obtained for the test samples. Supernatants obtained fol-
lowing lysostaphin digestion represented [3H]ECg firmly
bound to the cell wall and constituted 31% of total recovered
radioactivity. After lysis of protoplasts in hypotonic buffer and
collection of membranes by ultracentrifugation, the superna-
tant represented the intracellular fraction and contained 10.9%
of recovered 3H; 58.1% of total recovered radioactivity was
found in the membrane fraction. The values obtained were the
means of four experiments.
CM Changes Induced by ECg—Intercalation of ECg into the
CM will impact on the physical properties of the bilayer (15).
We therefore measured the effect of ECg onmembrane fluidity
using DPH; this hydrophobic fluorescent probe associates with
the lipophilic tails of phospholipids without disturbing bilayer
structure (44). A reduction in the freedom of rotation of the
probewill be reflected in increased emission of light in the same
plane as the excited light and a reduction in emission of light at
90° to the plane of excitation. There is therefore an inverse
relationship between the amount of polarized light emitted and
the fluidity of the membrane. When ECg was added to DPH-
loaded mid-logarithmic cultures of EMRSA-16, there was an
immediate, significant (p 0.005) increase inmembrane probe
polarization, indicating a reduction in fluidity (Fig. 1). When
bacteria were grown to mid-logarithmic phase in the presence
of ECg prior to the addition of DPH, there was significant (p
0.001) reduction in probe polarization, indicative of a more
fluid bilayer.
The polarization data strongly suggest that the bacteria
respond to binding of ECg by altering the composition of the
ECg-mediated Disruption of-Lactam Resistance
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CM.We therefore investigated the composition of phospholip-
ids extracted from ECg-grown and conventionally grown
EMRSA-16 cells. Two-dimensional TLC revealed up to 10
components in membranes from both cultures (Fig. 2); five
spots represented minor components, each constituting less
than 1% of total phospholipids, and were not investigated fur-
ther.Growth tomid-logarithmic phase in ECg reduced the con-
tent of the most prominent phospholipid, LPG, from 52.5 to
28.7%; there was a concomitant increase in PG from 34.8 to
61.7%, an increase in cardiolipin from 2.8 to 3.8%, and a signif-
icant reduction in lysophosphatidylglycerol from 6.5 to 1.5%.
Fatty acid moieties of these phospholipids ranged in length
from C10 to C21 with the most abundant being C16:0, C18:0,
C19:0, andC20:0 (Table 2). As previously reported for S. aureus
TABLE 1
Genes with increased expression of at least 2-fold following exposure to ECg, compared with cell wall stress stimulon up-regulation
determined in other studies
MRSA252a N315b Gene Product or putative function ECgc VISAd Vancomycind
Oxacillin
bacitracin
D-cycloserinee
Daptomycinf Functional category
SAR1340 SA1166 thrB Homoserine kinase 2.48 Amino acid biosynthesis
SAR1408 SA1228 dapB Dihydropicolinate synthase 2.66 Amino acid biosynthesis
SAR1339 SA1165 thrC Threonine synthase 3.06 Amino acid biosynthesis
SAR1407 SA1227 dapA Homoserine dehydrogenase 3.76 Amino acid biosynthesis
SAR1024 SA0903 Conserved hypothetical protein 2.33 3.6 Up Carbohydrate transport and
metabolism
SAR2522 SA2220 Glycerate kinase 2.88 Up 14.8 Carbohydrate transport and
metabolism
SAR1374 SA1195 msrR Reductase regulator 2.84 4.8 2.5 Transcription
SAR2394 SA2103 Transcriptional regulator 3.2 2.7 3.4 14 Regulation/transcription
SAR2585 SA2296 Transcriptional regulator,
MerR family
2.18 Regulatory functions
SAR1974 SA1700 vraR Response regulator 4.80 2.5 8.7 10.39 Signal transduction mechanism
SAR1975 SA1701 vraS Sensor histidine kinase 8.05 2.5 8.7 10.4 9.57 Signal transduction mechanism
SAR1976 SA1702 yvpF Conserved hypothetical protein 6.57 2.60 8.1 7.1 Function unknown
SAR1977 SA1703 Hypothetical protein 6.8 3.1 Up Function unknown
SAR0204 SA0205 Peptidase domain protein 2 4.5 Up Cell envelope biogenesis
SAR0273 SA0265 lytM Peptidoglycan hydrolase 2.58 4.8 2.2 Cell envelope biogenesis
SAR1030 SA0909 fmt Autolysis/methicillin resistance 4.11 Up Up 4.93 Cell envelope biogenesis
SAR1964 SA1691 sgtB Transglycosylase domain protein 5.47 2.9 10.6 8.10 Cell envelope biogenesis
SAR0251 SA0244 Teichoic acid biosynthesis protein 2.19 2.90 Cell envelope biogenesis
SAR2442 SA2146 tcaA TcaA protein 3.73 4.1 Up 3.03 Cell envelope
SAR1461 SA1283 pbp2 Penicillin binding protein 2 2.21 Cell envelope
SAR2212 SA1926 murZ UDP-GlcNAc-carboxytransferase 4.14 Cell envelope
SAR1932 SA1659 prsA Protease maturation protein 4.77 3.2 12 7.7 9.59 Protein turnover and chaperones
SAR1805 SA1549 htrA Serine protease HtrA 2.74 6.8 11 3.06 Protein turnover and chaperones
SAR0528 SA0483 clpC ATP-dependent Clp protease, ClpC 3.98 Protein turnover and chaperones
SAR0938 SA0835 clpB ATP-dependent Clp protease, CLpB 3.87 Protein turnover and chaperones
SAR1658 SA1410 grpE Heat shock protein GrpE 3.28 Protein folding and stabilization
SAR2117 SA1837 groES Chaperonin, 10 kDa 2.84 Protein folding and stabilization
SAR0513 SA0470 Chaperonin, 33 kDa 2.15 Protein folding and stabilization
SAR1230 SA1097 hslU Heat shock protein HslVU 2.12 Protein folding and stabilization
SAR2475 SA2175 heat shock protein Hsp20 3.08 Protein folding and stabilization
SAR2064 SA1777 Hypothetical protein 2.2 2.3 General function
SAR2388 SA2097 Secretory antigen precursor 2.04 4.8 General function
SAR0925 SA0824 Conserved hypothetical protein 3.19 2.1 5.8 Function unknown
SAR2690 SA2405 betA/cudB Choline dehydrogenase 5.94 Up Cell motility and secretion
SAR0927 SA0826 spsB Type-1 signal peptidase 1B 2.39 4.7 Up 2.56 Cell motility and secretion
SAR1851 SA1587 ribA Riboflavin biosynthesis protein 5.92 2.9 Coenzyme metabolism
SAR0580 SA0533 vraA Long chain fatty acid CoA ligase Lipid metabolism
SAR0581 SA0534 vraB Acetyl-CoA acetyltransferase 2.7 Lipid metabolism
SAR0582 SA0535 vraC Hypothetical protein 5.3 Function unknown
SAR0583 SA0536 vraY Hypothetical protein 2.9 Function unknown
SAR0584 vraX Hypothetical protein 24.2 22.7 224.7 26.6 Function unknown
SAR0645 SA0591 Hypothetical protein 3.7 5.3 Up Up Function unknown
SAR2509 SA2207 hlgA -Hemolysin, component A 10.18 Toxin production and resistance
SAR2770 SA2480 drp35 drP35 8.87 Toxin production and resistance
SAR2511 SA2209 hlgB -Hemolysin, component B 5.04 Toxin production and resistance
SAR2510 SA2208 hlgC g-Hemolysin, component C 3.52 Toxin production and resistance
SAR1035 SA0914 Similar to chitinase B 3.26 2.2 10.6 5.5
SAR1730 SA1476 Hypothetical protein 6.95 4 20.9
SAR1731 SA1477 Hypothetical protein 11.94 5.2 27.6
SAR1987 SA1712 Hypothetical protein 2.04 2 Up Up
SAR2065 SA1778 Hypothetical protein 2.4 2.2
SAR2184 SA1898 SceD protein 4.45 10.5
SAR2407 SA2113 Hypothetical protein 4.99 3.8 10.4
SAR2523 SA2221 Hypothetical protein 5.16 2.4 9.5 18.7
SAR2636 SA2343 Hypothetical protein 8.28 84.4 Up Up
SAR0599 SA0550 Hypothetical protein 2.2 Up
SAR2771 SA2481 Hypothetical protein 4.58 3.4 5.7
SAR2586 SA2297 GTP-pyrophosphokinase 2.0 8.6 Up
aMRSA252 ORF identifiers for the BG@S SAv1.1.0 microarray used in this study (30). ORF identifiers in bold form the genes of the core cell wall stress stimulon as defined by
McAleese et al. (40).
bN315ORF identifiers for the S. aureusN315microarray described byMcAleese et al. (40). ORF identifiers in bold form the genes of the core cell wall stress stimulon as defined
by McAleese et al. (40).
c Data from this study with S. aureus EMRSA-16.
d Up-regulation of cell wall stress stimulon genes induced by spontaneous mutation of a clinical S. aureus isolate to VISA and by exposure to suprainhibitory concentrations of
vancomycin (40).
e Up-regulated genes after exposure of S. aureus RN450 to these agents (38).
f Up-regulated genes after exposure of S. aureus ATCC 29213 to suprainhibitory concentrations of daptomycin (41).
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(45, 46), EMRSA-16 membranes contained a low percentage of
unsaturated fatty acids and a relative abundance of branched
chain fatty acids. There was no significant difference between
C-even and C-odd chain lengths of mid-logarithmic phase
(A600  0.7) cultures grown in MH broth or in broth supple-
mented with ECg (even number of C atoms: 69.5 and 68.4%,
respectively) and only minor variations in fatty acid chain
length between control and ECg-grown cultures (Table 2).
However, ECg-grown cultures contained a higher complement
of branched chain fatty acids compared with control cells
(22.5% compared with 15.5%); branched fatty acids are known
to increase the fluidity of the CM because of their inability to
form crystalline structures (47). The proportions of both iso
and anteiso fatty acids were increased by ECg; the latter confer
greater fluidizing properties on membranes than iso fatty acids
because they disturb packing order to a greater extent (46).
Because CM properties are known to be influenced by the
growth phase of the culture (46), we determined fatty acid com-
position in early logarithmic phase; whereas the proportion of
branched chain fatty acids in the control culture declined from
21.5% after 1 h growth to 18.4% after 2 h and 15.5% after 3 h, the
proportion did not change when EMRSA-16 was grown in the
presence of ECg (22.0% at 1 h, 22.4% at 2 h, and 22.5% at 3 h).
Effect of ECg on PBP2 Recruitment to the Septum—The sep-
tum is the main site of cell wall synthesis in S. aureus and
requires the presence of FtsZ; this key cell division protein
directly or indirectly recruits PBP2 to the septum during the
growth cycle (25). In strain COL spa, FtsZ was found to be
localized at the septum of cells grown tomid-logarithmic phase
using anti-FtsZ antiserum and fluorescence microscopy (data
not shown). We also calculated the amount of GFP-PBP2 fluo-
rescence at the septum compared with the nonseptal mem-
brane in dividing cells of the MRSA strain COLpPBP2-31 (Fig.
3). When grown in the absence of ECg, the GFP-PBP2 fusion
was localized at the septum, indicating that PBP2 was retained
to the site of cell division by the FtsZ-containing machinery
(Fig. 3A); oxacillin at a concentration of 4 g/ml had no effect
on the localization of the fusion in this MRSA strain (Fig. 3B).
Exposure to ECg did not affect the localization of FtsZ at the
septum of COL spa cells (data not shown) but was found to
delocalize the GFP-PBP2 fusion in COLpPBP2-31 (Fig. 3C); the
effect was even more pronounced in the presence of ECg and
oxacillin (Fig. 3D). Thismethodologycouldnotbeused to localize
PBP2a in the membrane because it has not proved possible to
engineerMRSA producing functional GFP-PBP2a fusions.5
Binding of ECg to PBPs—We investigated the possibility that
ECg binds to PBP2a and either blocks access to the active site or
alters its structure. PBPs were prepared from membranes
recovered from RUSA130; Tn551 insertion into the transpep-
tidase domain of PBP2produces a truncated formof the protein
and allows resolution of PBP2a, which migrates in a virtually
identical fashion to PBP2 in polyacrylamide gels (48). ECg was
incubated with the membrane extracts, and the mixture was
probed with Bocillin FL. At a concentration (12.5 g/ml) that
effects complete transition from-lactam resistance to full sus-
ceptibility inMRSA strains, ECg had no effect on the capacity of
Bocillin FL to bind to PBP2a (Fig. 4).
We then undertook studies with purified PBP2a; we deter-
mined the affinities of PBP2a for penicillin in competition stud-
ies with ECg (12.5 g/ml). In all assays, no differences in peni-
cillin-PBP2a binding were found even if (i) the time of
interaction between ECg and PBP2a was increased up to 24 h
(using both Bocillin FL (Fig. 5A) or benzyl[14C]penicillin); (ii)
the concentration of Bocillin in the assay was lowered in step-
wise fashion to below the level of detection in the assay (Fig. 5B);
or (iii) the concentration of ECg was increased (maximal con-
centration tested, 50 g/ml). PBP2a was then incubated in the
presence of increasing concentrations of [3H]ECg (0.8–3.5 g)
over 1 h, but in contrast to 14C-benzylpenicillin, no evidence for
complex formation between ECg and PBP2a was found. These
experiments were complemented by determination of the
kinetic parameters for interaction between nitrocefin (a ceph-
alosporin showing a distinctive change in the adsorption spec-
trum upon cleavage of the amide bond in the -lactam ring by
enzyme acylation) and PBP2a (see Ref 35 for experimental
design). As previously described, the minimal interaction
scheme assumes binding of nitrocefin (N) to the enzyme in an
initial noncovalent complex (EN), which proceeds to acylate
the active site serine of PBP2a and gives rise to the covalent
complex E-N. This covalent complex will ultimately undergo
hydrolytic deacylation. These studies indicate that preincuba-
tion of the protein with ECg (12.5 g/ml; 1 h) did not modify
either the dissociation constant for the formation of the preacy-
lation complex (Kd220 M), the PBP2a acylation rate con-
stant (k22 103 s1), or the deacylation rate constant (k3
3.7 106 s1). Examination of PBP2a folding by fluorescence
5 M. G. Pinho, unpublished data.
FIGURE 1. Membrane fluidity of MRSA-16 grown in the absence of ECg
(bar 1), grown tomid-logarithmic phase in 12.5g/ml of ECg (bar 2), and
grown to mid-logarithmic phase in ECg-free MH broth with the galloyl
catechin added and polarization determined immediately (bar 3). The
fluorescent probe DPH was incorporated into the CM as described under
“Experimental Procedures.” Thebars represent themeansS.D. (n15), and
the levels of significance were determined using paired Student’s t test.
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spectroscopy of tryptophan residues showed no differences
between untreated and ECg-treated PBP2a (Fig. 5C) compared
with denatured protein (1 h; 60 °C).
DISCUSSION
Exposure of multidrug-resistant
isolates of S. aureus to ECg elicits
phenotypic changes that are likely
to reduce the capacity of these
pathogens to produce severe sys-
temic infection. ECg compromises
biofilm formation, markedly sup-
presses the secretion of key viru-
lence determinants such as -toxin
and coagulase and, perhaps most
significantly, abrogates resistance to
-lactam antibiotics (9, 10). These
alterations are accompanied by a
marked change in the appearance of
cells when viewed by light or elec-
tronmicroscopy but not by a reduc-
tion in growth rate. Galloyl cat-
echins also reduce halotolerance in
staphylococci, probably by interfer-
ing with Na-specific antiporter
systems in the CM (49), and the
interrelatedness of these compo-
nents of the ECg-induced pheno-
type is emphasized by the capacity
of NaCl to prevent biofilm forma-
tion in much the same way as ECg.
The health promoting properties of
catechins have attracted much
attention and have been largely
attributed to their antioxidative,
free radical scavenging activities
(50), although they also modulate
the physical structure of phospholipid model bilayers and,
potentially, cellmembranes (15–18).Many proteins involved in
the regulation andmaintenance of bacterial growth andmetab-
olism reside in the CMand require a lipid environment to func-
tion; in addition, proteins embedded in the CM facilitate intra-
cellular and intercellular signaling. Thus, modulation of the
physical properties of the CM may be responsible for the gen-
eration of the complex phenotype elicited by incubation with
ECg.
Galloyl catechins, particularly those in the epi (cis) configu-
ration such as ECg and ()-epigallocatechin gallate, partition
into the phospholipid palisade, with their relative affinities for
membranes reflected in n-octanol-saline partition coefficients
(51), because of the presence of an exposed hydrophobic mem-
brane-perturbing domain (10). We sought clues to the molec-
ular processes involved in ECg-mediated -lactam sensitiza-
tion by examining changes in gene expression following
EMRSA-16 exposure to ECg. A significant proportion (38 of
103) of genes up-regulated in the logarithmic phase formedpart
of the cell wall stress stimulon associated with responses of
staphylococci to cell wall-active antibiotics, although genes of
this stimulon are also up-regulated by daptomycin. This
lipopeptide antibiotic functions primarily through disruption
of CM function (52). Many of these stress response genes are
FIGURE 2. Two-dimensional TLC analysis ofmembrane lipids extracted fromMRSA-16 grown tomid-loga-
rithmic phase (A600 0. 7) in the absence (A) or presence (B) of 12.5g/ml of ECg. The growthmedium (MH
broth) contained 18.5 KBq/ml of [32P]orthophosphate. The spots were visualized by autoradiography, and their
intensity was quantified using a Bio-Rad Molecular Imager FX; the data are presented in the bottom panel. CL,
cardiolipin; lysoPG, lysophosphatidylglycerol. TheLPGtotal is thesumofvaluesobtained fromspotsLPGandLPG-2.
Eachof theminorphospholipidcomponents fromECg-freeandECg-containingculturesconstituted less than1%of
total lipid extracted. The values given are the percentages of total lipid extracted S.D. (n 9).
TABLE 2
Fatty acid composition of phospholipids extracted from EMRSA-16
following growth to mid-logarithmic phase (grown to A600 0.7; 3 h
from broth inoculation) in ECg (12.5g/ml)
Fatty acid MH broth MH broth ECg
C10:0 0.48 0.07 0.65 0.05
C11:0 0.23 0.04 0.39 0.05
C12:0 0.62 0.07 0.54 0.07
isoC14:0 0.56 0.07 0.65 0.02
C14:0 8.19 0.72 4.84 0.50
isoC15:0 2.33 0.09 3.36 0.30
anteisoC15:0 3.31 0.15 4.82 0.28
C15:0 3.27 0.50 1.80 0.05
isoC16:0 0.86 0.07 0.97 0.06
C16:0 13.42 0.44 13.84 0.55
isoC17 1.52 0.03 2.09 0.12
anteisoC17:0 2.25 0.10 3.64 0.08
C17:0 3.01 0.17 2.32 0.14
C18:1,9 cis ol 2.49 0.46 3.92 0.61
C18:0 24.61 1.34 28.09 1.13
isoC19:0 1.24 0.10 1.57 0.03
anteisoC19:0 0.95 0.07 1.47 0.17
C19:0 9.82 0.30 7.35 0.45
C20:0 18.23 1.79 14.91 1.26
C21:0 2.62 0.18 2.78 0.16
% Branched (br) 15.51 22.49
% Non-branched (n-br) 84.49 77.51
Ratio (br/n-br) 0.18 0.29
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under the control of the two-component system VraRS that
positively regulates cell wall biosynthesis; orderly wall synthesis
is known to be perturbed following ECg exposure (12, 23). A
comparison of cell wall stress stimulon genesmodulated by cell
wall and membrane antibiotics (Table 1) reveals that the pat-
tern of up-regulation induced by ECg, with no antibiotic activ-
ity, is distinct from but more comparable with that engendered
by the cell wall biosynthesis inhibitors vancomycin and oxacil-
lin than by daptomycin. Thus, ECgmayhave cell wall andmem-
brane targets, or it may disrupt orderly cell wall assembly in a
nonlethal fashion by perturbing the lipid environment ofmem-
brane-bound enzymes involved in peptidoglycan biosynthesis.
Interestingly, although the ECg-induced stress response pat-
tern is strikingly similar to those genes overexpressed in VISA
clinical isolates (40), ECg had no effect on MRSA or VISA van-
comycin susceptibility.
Direct evidence for interactionwith the CMand cell wall was
obtained following exposure of EMRSA-16 to radiolabeled
ECg.Most (58%) of the label was found in the CM fraction with
a smaller proportion (31%) associated with the cell wall. ECg
intercalated rapidly into the CM as evidenced by an immediate
increase in polarization of the spin probe on exposure of DPH-
loaded bacteria to ECg, indicating an increase in the lipid order
of the CM. ECg is known to interact stably with hydrocarbon
chains in the bilayer of phospholipid model membranes, forc-
ing more tightly packed acyl chains (15). It is likely that these
abrupt changes will have a significant impact onmetabolic pro-
cesses associatedwith theCM, andwepresent evidence that the
targeted bacteria respond by radically altering the composition
and biophysical properties of the membrane; there is an
increase in the proportion of branched to nonbranched fatty
acids within phospholipids leading to “overcompensation” in
response to ECg-mediated perturbation. These changes may
improve the capacity of CM-associated cell wall biosynthetic
enzymes to continue to function in the presence of ECg, albeit
in suboptimal fashion. The proportion of ECg that bound to the
cell wall is significantly large but not unexpected, because entry
into and egress from the staphylococcal cell of hydrophilicmol-
ecules is to a large extent controlled by a complex continuumof
positive and negative charges within the wall matrix (24) and is
likely to reflect loosely bound ECg. We previously demon-
strated that exogenous peptidoglycan had no effect on the
capacity of ECg to reduce the MIC of oxacillin (12), suggesting
that binding is transient and does not blockade sites within the
cell wall that influence the sensitization mechanism.
The coupling of lysine to PG to yield LPG was markedly
reduced by growth in the presence of ECg. Whether this is a
bacterial response to CM intercalation or an inhibition of LPG
conjugation by ECg is currently unclear; lysine is attached to PG
byMprF, a CM-anchored protein that also translocates LPG to
the outer leaflet of the CM, where its positive charge profile
provides protection against host cationic antibacterial peptides
and daptomycin (53). Thus, mprF mutants are less virulent
when assessed in vitro and in vivo (54), and MprF has been
proposed as a novel target for anti-staphylococcal chemother-
apeutic drug development (53). Thus, ECg may elicit reduc-
tions in virulence potential over and above that caused by large
decreases in the secretion of enzymes and toxins (9, 55) by
reduction of the proportion of LPG in the membrane. In bio-
logicalmilieu, ECg forms complexeswithmonovalent anddiva-
lent metal ions (56) and thus carries an overall positive charge;
a reduction in LPG at the CM surface could increase the inter-
action of ECg-metal ion complexes with the phospholipid pal-
isade caused by decreased electrostatic repulsion. LPG head
groups in all likelihood contribute to the complex charge
FIGURE 3. Location of PBP2 in MRSA strain COLpPBP2-31 as determined
by fluorescence microscopy. This strain carries a gfp-pbp2 fusion. The bac-
teria were visualized after growth in MH broth (A) and in broth containing 4
g/ml oxacillin (B), 12.5 g/ml ECg (C), and 4 g/ml oxacillin and 12.5 g/ml
ECg (D). The extent of localization of PBP2 at the septum was determined by
calculating the ratio (a c/b c), where a stands for fluorescence found at
the septum, b stands for fluorescence at the lateral membrane, and c stands
for background fluorescence (E). The values are the means S.D. frommea-
surement of fluorescence ratios of 200 cells in each sample. A ratio (a c/b
c) greater than 2 indicates localization at the septum, where twomembranes
are present, whereas a ratio of 2 or less than two indicates delocalization (59).
FIGURE 4. Binding of the fluorescent penicillin derivative Bocillin FL to
PBPs recovered from RUSA130 and exposed to 12.5 g/ml ECg. This
strain produces a truncated formof PBP2 andenables thedetection of PBP2a,
whichmigrates in gels in an identical fashion to native PBP2. After incubation
with ECg, the samples were labeled with 25 M Bocillin FL and separated by
10% SDS-PAGE, and the proteins were detected by fluorography., no ECg.
TruncatedPBP2has very lowaffinity for-lactamagents (29, 48) anddoesnot
bind sufficient Bocillin FL for visualization on the gel.
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matrix at or near the staphylococcal surface, and a reduced
complement of LPG-related positive charges probably contrib-
ute, along with reduced wall teichoic acid D-alanylation (23), to
amore negatively charged surface. Such ECg-modified bacteria
are likely to lose their capacity to form biofilms on artificial
surfaces because of electrostatic repulsion (12).
In staphylococci, the new cell wall is synthesized mainly, if
not exclusively, at the septum and is dependent on the for-
mation of an FtsZ ring that ensures the cell wall biosynthetic
machinery remains localized at the septation site throughout
the cell division cycle (57, 58). In MRSA, the functional
cooperation between PBP2 and PBP2a is maintained in the
presence of -lactam agents, growth and cell division pro-
ceed in orderly fashion and PBP2, and presumably PBP2a are
found at the septum (26). In this study we show that ECg
delocalizes PBP2 from the septum, and this is likely to con-
tribute to the gross morphological changes that ECg induces
in the absence of -lactam agents. MRSA strains are sensi-
tized to oxacillin even when PBP2a is constitutively expressed
(11), suggesting either that PBP2a is also delocalized from the
septum or that PBP2 and PBP2a are functionally decoupled,
and PBP2a is no longer able to compensate for the loss of PBP2
transpeptidase activity in the presence of oxacillin. Delocaliza-
tion of PBP2 would abrogate peptidoglycan chain extension at
the site of cell division, an event with significant consequences
on cell replication (57).
We have no evidence that ECg engenders greater physical
separation of these proteins in the membrane or that the
changes in the fluid dynamics of the membrane are responsible
for the decoupling. In fact, there is little or no evidence in the
literature that PBP2 and PBP2a form a close physical associa-
tion within the membrane, although intuitively one would
expect the functional cooperation between the two proteins to
be manifest through formation of such a complex. The division
site appears to be enriched for certain phospholipids (58), sug-
gesting that the lipid composition at the septum plays a role in
the assembly and maintenance of the biosynthetic machinery;
ECg-induced rearrangement of the membrane bilayer may
therefore contribute to PBP delocalization by inducing a sub-
optimal lipid environment for these membrane-anchored
proteins.
There is evidence that PBP2 recruitment to the septum is
at least partially dependent on recognition of the substrate,
because covalent modification of the active site with -lac-
tams or blocking of the D-Ala-D-Ala terminus of the peptide
stem of peptidoglycan with vancomycin results in delocal-
ization (26, 58). It has been suggested (58) that -lactam-
mediated inactivation of the transpeptidase domain of PBP2
allows PBP2a, which has a low affinity for -lactams, to bind
effectively to peptidoglycan (its substrate) at the septum.
This in turn allows the recruitment of PBP2 to ensure con-
tinued transglycosylation and transpeptidation in the pres-
ence of the antibiotic. Such a process is clearly disrupted by
ECg and may be related to gross changes to the lipid envi-
ronment as discussed above. It could also occur, however, if
ECg bound directly to PBP2a and induced a conformational
change that allowed acylation of the active site, as occurs at
low pH (36). We therefore examined the interaction of ECg
with PBP2a; incubation of PBPs with ECg did not alter their
capacity to bind Bocillin FL and had no impact on kinetic
properties (as measured by acylation and deacylation stud-
ies) or on the folded structure of PBP2a (as determined by
tryptophan fluorescence spectroscopy). We think it likely,
therefore, that changes in the lipid composition of the CM
provide an environment that is incompatible with mainte-
nance of the biosynthetic machinery at the division site.
In summary, we provide evidence that ECg binds to the
CM of MRSA and penetrates deep into the hydrophobic
region of the bilayer, leading to tighter acyl chain packing, a
reduction in membrane fluidity, and nonlethal perturbation
of cell wall synthesis. The bacteria recover by reconfiguring
the membrane; a reduction in LPG, likely to affect virulence,
is accompanied by an increase in branched chain fatty acid
moieties of the phospholipids, resulting in the elaboration of
FIGURE 5. -Lactam binding (A and B) and fluorescence assay (C) of PBP2a in 25 mM HEPES, 1 M NaCl (pH 7. 0). A, binding of the fluorescent penicillin
derivative Bocillin FL toPBP2a (5M). PBP2awas incubated for up to24h in 12.5g/ml ECg. The sampleswere then incubated for 25min in thepresenceof 1.25
g of Bocillin FL and prepared for fluorescencemeasurement. The results were expressed as percentages of change from controls (no ECg added). The values
are themeans S.D. B, binding of increasing concentrations of Bocillin FL to PBP2a (5M). PBP2awas incubated over 1 h in 12.5g/ml ECg. Bindingwas then
measured after 25min in thepresence of increasing concentrations of Bocillin FL. The values are themeans S.D.C, tryptophan fluorescence emission spectra
of PBP2a (0.18 g/ml). The pretreatments of PBP2a are as follows: ECg added (1 h, 12.5 g/ml) and denatured protein (1 h, 60 °C). We have previously
determined (36) that the Bocillin FL concentrations employed in these experiments enable the detection of changes in the affinity of PBP2a for -lactam
antibiotics.
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a bilayer with higher overall fluidity than that found in non-
treated cells. We propose that these gross changes in mem-
brane fluid dynamics uncouple at least some components
from the peptidoglycan biosynthetic machinery at the sep-
tum, resulting in delocalization of PBP2 and eventually also
of PBP2a or abrogating the functional cooperation between
PBP2 and PBP2a that allows cell wall synthesis to proceed
normally in the presence of -lactam agents. Decoupling
does not appear to involve direct interactions between ECg
and PBP2a. A smaller proportion of ECg can be recovered
from the cell wall, and it is possible that ECg binds to nascent
peptidoglycan in the wall and uncouples PBP2/PBP2a from
substrate, a hypothesis that requires elucidation.
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